Dr Yuki Sato, Head, Division of Cell-Based Therapeutic Products from National Institute of Health Sciences gave a presentation on the latest landscape of the Japanese regulations on regenerative medicines.
The presentation explains the differences between the two relevant Acts:
- Regenerative Medicine Safety Act for medical practices using processed cells
- Pharmaceuticals and Medical Devices Act.
The presentation material is available here.
This was a part of a webinar session co-organised by DIT Japan, Cell & Gene Therapy Catapult and Kanagawa Prefecture in November 2020 to raise awareness of the UK’s Advanced therapy ecosystem and share the latest technological development and regulations.
